Biocon Biologics, a subsidiary of Biocon, on Thursday said it will offer around 15 per cent stake to Serum Institute Life Sciences at a post-money valuation of about USD 4.9 billion.
Serum Institute Life Sciences (SILS) is a subsidiary of Serum Institute of India (SII).
For offering the 15 per cent stake, Biocon Biologics Ltd (BBL) will get committed access to 100 million doses of vaccines per annum for 15 years, primarily from SILS’ upcoming vaccine facility in Pune with commercialisation rights of the SILS vaccine portfolio, including COVID-19 vaccines, for the global market, Biocon said in a regulatory filing.
“Pursuant to the terms of …
Related posts:
14th Round Of India-China Military Talks Fails On Outcome But Scores On Cordiality
CBI Arrests DSIIDC Sr Official, Private Person For Accepting Bribe Of Rs 1.70 Lakh
SBI Successfully Prices Its First International USD Denominated Public Bond For $300 Mn
Shipping congestion is growing at world’s biggest port
